anti-PD-1 antibodies tagged posts

Immunotherapy combo that encourages immune cells to consume tumors could lead to long-term remission for glioblastoma. A combination of immunotherapy agents that encourages some immune cells to eat cancer cells and alert others to attack tumors put mice with a deadly type of brain cancer called glioblastoma into long-term remission, a new study led by UT Southwestern scientists suggests. The finding, published online March 20, 2020, in Nature Communications, could lead to new therapies that may significantly extend survival for human glioblastoma patients, which stands at an average of 15 months after diagnosis even with current state-of-the-art therapies.

The immune system has two branches: innate immunity, an evolutionarily older system that continually scans the b...

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody.

Biomedical engineering researchers have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

More than 67,000 people in the US were diagnosed with melanoma in 2012 alone – the most recent year for which data are available. If caught early, melanoma patients have a 5yr survival rate of more than 98%. That number dips to 16.6% if the cancer has metastasized before diagnosis and treatment.

Cancer cells can trick T cells...